SCHEMBL9924262

SCHEMBL9924262

O=C(/N=C(/Nc1cccc(Cl)c1)N[C@H]1CC[C@H](O)CC1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 2/20 0.46
DCUN1D1 Q96GG9 2/20 0.46
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
EPHX2 P34913 2/20 0.44
NPC1 O15118 2/20 0.44
LMNA P02545 2/20 0.44
RAB9A P51151 2/20 0.44
EPHX1 P07099 1/20 0.44
TSHR P16473 1/20 0.44
TRPV1 Q8NER1 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
PTGS1 P23219 1/20 0.42
ACKR3 P25106 2/20 0.42
MAPT P10636 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924227 0.91 EPHX2 (0.52) UBE2MDCUN1D1MEN1KMT2AEPHX2
SCHEMBL17206706 0.90 DCUN1D1 (0.52) UBE2MDCUN1D1MEN1KMT2AEPHX2
SCHEMBL9924214 0.90 MEN1 (0.49) MEN1KMT2AEPHX2NPC1LMNA
SCHEMBL9924130 0.89 DCUN1D1 (0.52) UBE2MDCUN1D1MEN1KMT2AEPHX2
SCHEMBL9924261 0.87 TRPV1 (0.42) MEN1KMT2AEPHX2TRPV1MRGPRX4
SCHEMBL9924131 0.87 NPC1 (0.50) MEN1KMT2AEPHX2NPC1LMNA
SCHEMBL17206718 0.86 UBE2M (0.43) UBE2MDCUN1D1MEN1KMT2AEPHX2
SCHEMBL9924260 0.86 MEN1 (0.46) MEN1KMT2AEPHX2NPC1LMNA
SCHEMBL17206709 0.85 TRPV1 (0.42) MEN1KMT2AEPHX2TRPV1MRGPRX4
SCHEMBL9924226 0.84 EPHX2 (0.53) UBE2MDCUN1D1MEN1KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed